Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Dupilumab (Dupixent) is used for a variety of indications including moderate-to-severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis.
• A review of 31 systematic reviews/meta-analyses reveals that Dupilumab shows higher efficacy in reducing symptoms and improving the quality of life compared to placebo across various conditions.
• In the treatment of Atopic Dermatitis (AD), it has been found beneficial, especially among pediatric populations. However, direct comparisons suggest upadacitinib and abrocitinib might offer superior short-term efficacy but often come with a higher risk of adverse events.
• For patients suffering from asthma characterized by an eosinophilic phenotype or dependence on oral corticosteroids, Dupilumab improves lung function while reducing exacerbations; however, newer pharmaceuticals like Umeclidinium/Vilanterol may show better improvements in FEV1 measurements.
• When treating Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP), this drug significantly improves quality-of-life measures and reduces polyp surgery risk making it one the most beneficial biologics for CRSwNP when compared to others such as omalizumab and mepolizumab.
• Considering all indications together, high-dose upadacitinib was found to be more effective but also more harmful than Dupilumab, which offered intermediate effectiveness along with a significantly better safety profile marked by less increase in conjunctivitis compared to other drugs like lebrikizumab and tralokinumab.
• The benefits are particularly significant among pediatric populations where studies consistently indicate symptom relief along with notable improvements in disease-specific quality-of-life measurements using Dupilumab.
• Dupilumab's safety profile has been favorable across studies, showing lower incidence rates of serious adverse events compared to several other biologics and systemic treatments.